$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000106282218000026 Filed on July 30, 2018

Income Statement

Concept	2018 Q2	2017 Q2
Revenue	$13.80M	$12.09M
YoY Change	14.16%	-39.83%
Cost Of Revenue	$838.0K	$537.0K
YoY Change	56.05%
Gross Profit	$12.96M	$11.55M
YoY Change	12.21%	-42.51%
Gross Profit Margin	93.93%	95.56%
Selling, General & Admin	$16.80M	$18.48M
YoY Change	-9.07%	119.52%
% of Gross Profit	129.63%	159.96%
Research & Development	$26.48M	$26.93M
YoY Change	-1.7%	-44.14%
% of Gross Profit	204.3%	233.19%
Depreciation & Amortization	$1.000M	$1.000M
YoY Change	0.0%	100.0%
% of Gross Profit	7.72%	8.66%
Operating Expenses	$44.07M	$45.95M
YoY Change	-4.08%	-19.55%
Operating Profit	-$30.27M	-$33.49M
YoY Change	-9.61%	-9.54%
Interest Expense	$5.187M	$1.614M
YoY Change	221.38%	-1.47%
% of Operating Profit
Other Income/Expense, Net	$910.0K	$448.0K
YoY Change	103.13%	-18.1%
Pretax Income	-$34.71M	-$35.06M
YoY Change	-1.01%	-8.01%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$34.55M	-$34.66M
YoY Change	-0.31%	-9.07%
Net Earnings / Revenue	-250.39%	-286.73%
Basic Earnings Per Share
Diluted Earnings Per Share	-$326.1K	-$333.3K
COMMON SHARES
Basic Shares Outstanding	105.8M shares	105.2M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q2	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$209.7M	$231.2M
YoY Change	-9.3%	-46.16%
Cash & Equivalents	$48.90M	$30.71M
Short-Term Investments	$194.6M	$200.5M
Other Short-Term Assets	$3.954M	$10.17M
YoY Change	-61.14%	12.16%
Inventory	$2.142M	$811.0K
Prepaid Expenses
Receivables	$4.406M	$5.014M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$220.2M	$247.2M
YoY Change	-10.92%	-43.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$16.77M	$18.59M
YoY Change	-9.77%	-8.66%
Goodwill	$44.54M	$44.54M
YoY Change	0.0%	0.0%
Intangibles	$51.00M	$52.77M
YoY Change	-3.35%	-1.1%
Long-Term Investments
YoY Change
Other Assets	$429.0K	$428.0K
YoY Change	0.23%	-0.47%
Total Long-Term Assets	$112.7M	$116.3M
YoY Change	-3.08%	-1.98%
TOTAL ASSETS
Total Short-Term Assets	$220.2M	$247.2M
Total Long-Term Assets	$112.7M	$116.3M
Total Assets	$332.9M	$363.5M
YoY Change	-8.41%	-34.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$50.45M	$43.86M
YoY Change	15.04%	55.38%
Accrued Expenses	$12.87M	$10.96M
YoY Change	17.39%	-54.24%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$12.90M	$15.16M
YoY Change	-14.91%	-12.34%
Total Short-Term Liabilities	$81.34M	$133.2M
YoY Change	-38.92%	1.66%
LONG-TERM LIABILITIES
Long-Term Debt	$232.2M	$85.38M
YoY Change	171.95%	0.56%
Other Long-Term Liabilities	$265.0K	$313.0K
YoY Change	-15.34%	-97.77%
Total Long-Term Liabilities	$232.5M	$85.70M
YoY Change	171.26%	-13.39%
TOTAL LIABILITIES
Total Short-Term Liabilities	$81.34M	$133.2M
Total Long-Term Liabilities	$232.5M	$85.70M
Total Liabilities	$338.0M	$257.2M
YoY Change	31.42%	-24.53%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.444B	-$1.322B
YoY Change	9.2%	11.88%
Common Stock	$106.0K	$105.0K
YoY Change	0.95%	0.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.876M	$1.904M
YoY Change	51.05%	-43.47%
Treasury Stock Shares	236.0K shares	122.0K shares
Shareholders Equity	-$5.071M	$106.3M
YoY Change
Total Liabilities & Shareholders Equity	$332.9M	$363.5M
YoY Change	-8.41%	-34.87%

Cashflow Statement

Concept	2018 Q2	2017 Q2
OPERATING ACTIVITIES
Net Income	-$34.55M	-$34.66M
YoY Change	-0.31%	-9.07%
Depreciation, Depletion And Amortization	$1.000M	$1.000M
YoY Change	0.0%	100.0%
Cash From Operating Activities	-$52.50M	-$32.20M
YoY Change	63.04%	-32.78%
INVESTING ACTIVITIES
Capital Expenditures	-$100.0K	-$100.0K
YoY Change	0.0%
Acquisitions
YoY Change
Other Investing Activities	$47.40M	$56.90M
YoY Change	-16.7%	-7.63%
Cash From Investing Activities	$47.30M	$56.70M
YoY Change	-16.58%	-7.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-200.0K	3.700M
YoY Change	-105.41%
NET CHANGE
Cash From Operating Activities	-52.50M	-32.20M
Cash From Investing Activities	47.30M	56.70M
Cash From Financing Activities	-200.0K	3.700M
Net Change In Cash	-5.400M	28.20M
YoY Change	-119.15%	107.35%
FREE CASH FLOW
Cash From Operating Activities	-$52.50M	-$32.20M
Capital Expenditures	-$100.0K	-$100.0K
Free Cash Flow	-$52.40M	-$32.10M
YoY Change	63.24%	-32.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-33000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-419000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
	dei	Document Type DocumentType	10-Q
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6296000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-481000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1169000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-20797000	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	105878614	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	LEXICON PHARMACEUTICALS, INC./DE
CY2018Q2	lxrx	Buildings Collateral BuildingsCollateral	59200000	USD
CY2017Q2	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	0	USD
	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	2101000	USD
CY2018Q2	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	0	USD
	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	0	USD
CY2014Q4	lxrx	Conv Debt Instrument Interest Rate Stated Percentage ConvDebtInstrumentInterestRateStatedPercentage	0.0525
CY2017Q4	lxrx	Deferred Tax Assetremeasured DeferredTaxAssetremeasured	171400000	USD
CY2007Q2	lxrx	Holdings Contribution To Icon HoldingsContributionToIcon	45000000	USD
	lxrx	Ipsen Maximum Regulatory And Commercial Milestones IpsenMaximumRegulatoryAndCommercialMilestones	13000000	USD
CY2014Q4	lxrx	Ipsen Maximum Sales Milestones IpsenMaximumSalesMilestones	72000000	EUR
CY2016Q3	lxrx	Ipsen Milestone Payment IpsenMilestonePayment	6400000	USD
	lxrx	Ipsen Milestone Payment IpsenMilestonePayment	6400000	USD
	lxrx	Ipsen Milestone Payment IpsenMilestonePayment	5100000	USD
CY2017Q4	lxrx	Ipsen Milestone Payment Received IpsenMilestonePaymentReceived	3840000	USD
CY2017Q4	lxrx	Ipsen Milestone Payment Received IpsenMilestonePaymentReceived	3840000	USD
CY2017Q3	lxrx	Ipsen Milestone Payment Received IpsenMilestonePaymentReceived	5100000	USD
	lxrx	Ipsen Product Revenue IpsenProductRevenue	200000	USD
	lxrx	Ipsen Product Revenue IpsenProductRevenue	1400000	USD
CY2014Q4	lxrx	Ipsen Revenue Allocatedto Committee Deliverable IpsenRevenueAllocatedtoCommitteeDeliverable	100000	USD
CY2014Q4	lxrx	Ipsen Revenue Allocatedto Development Deliverable IpsenRevenueAllocatedtoDevelopmentDeliverable	1700000	USD
CY2014	lxrx	Ipsen Revenue Allocatedto License Deliverable IpsenRevenueAllocatedtoLicenseDeliverable	21200000	USD
CY2015	lxrx	Ipsen Revenue Allocatedto License Deliverable IpsenRevenueAllocatedtoLicenseDeliverable	1400000	USD
	lxrx	Ipsen Revenue Recognized IpsenRevenueRecognized	1400000	USD
	lxrx	Ipsen Revenue Recognized IpsenRevenueRecognized	600000	USD
CY2018Q2	lxrx	Ipsen Total Payments IpsenTotalPayments	43700000	USD
CY2015Q1	lxrx	Ipsen Total Upfront Payments IpsenTotalUpfrontPayments	24500000	USD
CY2018Q2	lxrx	Land Collateral LandCollateral	2700000	USD
CY2010Q3	lxrx	Lexicon Paid Holdings Cash LexiconPaidHoldingsCash	10000000	USD
CY2007Q2	lxrx	Lexicon Received Cash From Holdings LexiconReceivedCashFromHoldings	15000000	USD
CY2007Q2	lxrx	Lexicon Sold Shares To Holdings LexiconSoldSharesToHoldings	1092946	shares
CY2018Q2	lxrx	Lxrxdebtinstrumentformortgagestatedinterestrate Lxrxdebtinstrumentformortgagestatedinterestrate	0.0823
CY2017Q2	lxrx	Netproductrevenue Netproductrevenue	3892000	USD
	lxrx	Netproductrevenue Netproductrevenue	4613000	USD
CY2018Q2	lxrx	Netproductrevenue Netproductrevenue	7316000	USD
	lxrx	Netproductrevenue Netproductrevenue	12776000	USD
CY2015Q4	lxrx	Sanofi Commercialization Costs Fundedby Lexicon Maximum Amount SanofiCommercializationCostsFundedbyLexiconMaximumAmount	100000000	USD
CY2015Q4	lxrx	Sanofi Development Milestones SanofiDevelopmentMilestones	110000000	USD
CY2015Q4	lxrx	Sanofi Outcomes Study Milestone SanofiOutcomesStudyMilestone	100000000	USD
CY2015Q4	lxrx	Sanofi Regulatory Milestones SanofiRegulatoryMilestones	220000000	USD
CY2015Q4	lxrx	Sanofi Revenue Allocatedto Development Deliverable SanofiRevenueAllocatedtoDevelopmentDeliverable	113800000	USD
CY2015Q4	lxrx	Sanofi Revenue Allocatedto Funding Deliverable SanofiRevenueAllocatedtoFundingDeliverable	59400000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4825000	USD
	lxrx	Sharebased Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Periodto Board SharebasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodtoBoard	20512	shares
	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	31612000	USD
	lxrx	Share Based Compensation Arrangementby Sharebased Payment Award Equity Instructions Other Than Options Vested Immediately Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementbySharebasedPaymentAwardEquityInstructionsOtherThanOptionsVestedImmediatelyWeightedAverageGrantDateFairValue	7.80
CY2015Q4	lxrx	Sanofi Revenue Allocatedto License Deliverable SanofiRevenueAllocatedtoLicenseDeliverable	126800000	USD
	lxrx	Sanofi Revenue Recognized SanofiRevenueRecognized	24100000	USD
	lxrx	Sanofi Revenue Recognized SanofiRevenueRecognized	25100000	USD
CY2015Q4	lxrx	Sanofi Sales Milestone Payments SanofiSalesMilestonePayments	990000000	USD
CY2015Q4	lxrx	Sanofi Upfront Payment SanofiUpfrontPayment	300000000	USD
CY2017Q2	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	18475000	USD
	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	33346000	USD
CY2018Q2	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	16755000	USD
	lxrx	Shares Issued To Symphony Designees Value SharesIssuedToSymphonyDesigneesValue	10499000	USD
	lxrx	Shares Issued To Symphony Designees Value SharesIssuedToSymphonyDesigneesValue	0	USD
CY2017Q2	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1169000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	2353000	USD
CY2018Q2	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1395000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	3050000	USD
CY2017Q2	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	1234000	USD
	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	2281000	USD
CY2018Q2	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	1503000	USD
	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	2922000	USD
CY2010Q3	lxrx	Symphon Fair Value Of Base And Contingent Payments SymphonFairValueOfBaseAndContingentPayments	45600000	USD
CY2016Q3	lxrx	Symphony Amendment Buyout SymphonyAmendmentBuyout	21000000	USD
CY2010Q3	lxrx	Symphony Base Payment Discount Rate SymphonyBasePaymentDiscountRate	0.14
CY2012Q3	lxrx	Symphony Base Payment In Shares SymphonyBasePaymentInShares	1891074	shares
CY2012Q3	lxrx	Symphony Base Payment Obligation SymphonyBasePaymentObligation	35000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Discount Rate SymphonyContingentPaymentDiscountRate	0.18
CY2014Q4	lxrx	Symphony Contingent Payment In Cash SymphonyContingentPaymentInCash	5800000	USD
CY2015Q2	lxrx	Symphony Contingent Payment In Cash SymphonyContingentPaymentInCash	750000	USD
CY2016Q3	lxrx	Symphony Contingent Payment In Cash SymphonyContingentPaymentInCash	3200000	USD
CY2017Q1	lxrx	Symphony Contingent Payment In Cash SymphonyContingentPaymentInCash	10500000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Maximum SymphonyContingentPaymentMaximum	45000000	USD
CY2010Q3	lxrx	Symphony Contingent Payment Percentage SymphonyContingentPaymentPercentage	0.50
CY2014Q4	lxrx	Symphony Contingent Payment Total SymphonyContingentPaymentTotal	11500000	USD
CY2014Q4	lxrx	Symphony Contingent Paymentin Shares SymphonyContingentPaymentinShares	666111	shares
CY2017Q1	lxrx	Symphony Contingent Paymentin Shares SymphonyContingentPaymentinShares	659905	shares
CY2010Q3	lxrx	Symphony Payment In Stock Limitation SymphonyPaymentInStockLimitation	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Payment SymphonyRegulatoryApprovalPayment	15000000	USD
CY2010Q3	lxrx	Symphony Regulatory Approval Percentage Limit SymphonyRegulatoryApprovalPercentageLimit	0.50
CY2010Q3	lxrx	Symphony Regulatory Approval Reduction Percentage SymphonyRegulatoryApprovalReductionPercentage	0.50
	lxrx	Xermelo Intangible Assets Finite Lived XERMELOIntangibleAssetsFiniteLived	24700000	USD
CY2004Q2	lxrx	Xrxdebtinstrumentformortgage Xrxdebtinstrumentformortgage	34000000	USD
	lxrx	Xrxdebtinstrumentformortgage Xrxdebtinstrumentformortgage	12900000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	57652000	USD
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	50451000	USD
CY2018Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4406000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12282000	USD
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12865000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	58623000	USD
CY2018Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	59459000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-222000	USD
CY2018Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-218000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1435526000	USD
CY2018Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1441890000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4634000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5972000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4000	USD
CY2018Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	254000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	592000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	600000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	900000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2017Q4	us-gaap	Assets Assets	436539000	USD
CY2018Q2	us-gaap	Assets Assets	332937000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	321995000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	220191000	USD
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	249127000	USD
CY2018Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	194645000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46600000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30706000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61661000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15044000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	61661000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	15044000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-15894000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-46617000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	106000	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	106000	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35009000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-69969000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-34531000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-76777000	USD
CY2017Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	537000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	762000	USD
CY2018Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	838000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1371000	USD
CY2014Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	8.442
CY2014Q4	us-gaap	Debt Instrument Convertible Conversion Ratio1 DebtInstrumentConvertibleConversionRatio1	118.4553
CY2017Q4	us-gaap	Debt Instrument Description DebtInstrumentDescription	200000000
CY2017Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	150000000	USD
CY2018Q2	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	145900000	USD
CY2018Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0900
CY2018Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	3700000	USD
CY2017Q2	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-8652000	USD
CY2018Q2	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2017Q4	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	4100000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-8652000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	40099000	USD
CY2018Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	5124000	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	22428000	USD
CY2018Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	18195000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	6014000	USD
CY2018Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	6014000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1552000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1853000	USD
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.67
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.73
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	2101000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1471000	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2354000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-2000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2017Q4	us-gaap	Goodwill Goodwill	44543000	USD
CY2018Q2	us-gaap	Goodwill Goodwill	44543000	USD
CY2018Q2	us-gaap	Guarantee Obligations Maximum Exposure GuaranteeObligationsMaximumExposure	2900000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-35059000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-78602000	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-34706000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-76781000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-22269000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-6644000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2478000	USD
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	64000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-24996000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	811000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	194000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	51885000	USD
CY2018Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	51002000	USD
CY2017Q2	us-gaap	Interest Expense InterestExpense	1614000	USD
	us-gaap	Interest Expense InterestExpense	3202000	USD
CY2018Q2	us-gaap	Interest Expense InterestExpense	5187000	USD
	us-gaap	Interest Expense InterestExpense	10301000	USD
	us-gaap	Interest Paid Net InterestPaidNet	2956000	USD
	us-gaap	Interest Paid Net InterestPaidNet	6726000	USD
CY2017Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1183000	USD
CY2018Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1050000	USD
CY2017Q4	us-gaap	Inventory Gross InventoryGross	1948000	USD
CY2018Q2	us-gaap	Inventory Gross InventoryGross	2142000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	1948000	USD
CY2018Q2	us-gaap	Inventory Net InventoryNet	2142000	USD
CY2017Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	616000	USD
CY2018Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	961000	USD
CY2017Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	149000	USD
CY2018Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	131000	USD
CY2017Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	310788000	USD
CY2018Q2	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	209689000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	384437000	USD
CY2018Q2	us-gaap	Liabilities Liabilities	338008000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	436539000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	332937000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	124127000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	81336000	USD
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	14094000	USD
CY2018Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	12896000	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	231576000	USD
CY2018Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	232198000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2586000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1749000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	99241000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	54430000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-117721000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-99298000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-35059000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-69950000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-34706000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-76781000	USD
CY2017Q2	us-gaap	New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification	0	USD
	us-gaap	New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification	14212000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	45946000	USD
	us-gaap	Operating Expenses OperatingExpenses	106724000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	44182000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	978000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-19000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	175000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	4000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	292000	USD
CY2018Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	265000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	448000	USD
	us-gaap	Operating Expenses OperatingExpenses	107355000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-33893000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-76378000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-30429000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-68395000	USD
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4434000	USD
CY2018Q2	us-gaap	Other Assets Current OtherAssetsCurrent	3954000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	429000	USD
CY2018Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	429000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	50000	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	910000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1915000	USD
CY2014Q4	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	3400000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1679000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	972000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	59989000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	49638000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	163000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	55000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2018Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	87500000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5427000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	392000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	159393000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	104123000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	17687000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	16772000	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	-7000	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1162000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26934000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	70515000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26589000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	74372000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1381404000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1443973000	USD
CY2017Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	8104000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	25669000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	6359000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	26024000	USD
CY2017Q2	us-gaap	Revenues Revenues	12053000	USD
	us-gaap	Revenues Revenues	30346000	USD
CY2018Q2	us-gaap	Revenues Revenues	13753000	USD
	us-gaap	Revenues Revenues	38960000	USD
CY2017Q2	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	57000	USD
CY2018Q2	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	78000	USD
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	160000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4634000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5972000	USD
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	249127000	USD
CY2018Q2	us-gaap	Short Term Investments ShortTermInvestments	194645000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5427000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	392000	USD
	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	0	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	52102000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	-5071000	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	157401000	USD
CY2017Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	106313000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	52102000	USD
CY2018Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-5071000	USD
CY2017Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	122000	shares
CY2018Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	236000	shares
CY2017Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1904000	USD
CY2018Q2	us-gaap	Treasury Stock Value TreasuryStockValue	2876000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1679000	USD
	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	972000	USD
CY2018Q2	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	1600000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-19000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	4000	USD
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	105300000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	104883000	shares
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	105848000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	105758000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentration of Credit Risk:</font><font style="font-family:inherit;font-size:10pt;"> Lexicon’s cash equivalents, investments and accounts receivable represent potential concentrations of credit risk. The Company attempts to minimize potential concentrations of risk in cash equivalents and investments by placing investments in high-quality financial instruments. The Company’s accounts receivable are unsecured and are concentrated in pharmaceutical and biotechnology companies located in Europe and the United States.  The Company has not experienced any significant credit losses to date.  </font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates:</font><font style="font-family:inherit;font-size:10pt;"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001062822-18-000026-index-headers.html	Edgar Link	pending
0001062822-18-000026-index.html	Edgar Link	pending
0001062822-18-000026.txt	Edgar Link	pending
0001062822-18-000026-xbrl.zip	Edgar Link	pending
exh311certificationofprinc.htm	Edgar Link	pending
exh312certificationofprinc.htm	Edgar Link	pending
exh321certificationofprinc.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lxrx-20180630.xml	Edgar Link	completed
lxrx-20180630.xsd	Edgar Link	pending
lxrx-20180630_cal.xml	Edgar Link	unprocessable
lxrx-20180630_def.xml	Edgar Link	unprocessable
lxrx-20180630_lab.xml	Edgar Link	unprocessable
lxrx-20180630_pre.xml	Edgar Link	unprocessable
lxrx630201810-q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2018 Q2 Form 10-Q Financial Statement

#000106282218000026 Filed on July 30, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2018 Q2 Form 10-Q Financial Statement

#000106282218000026 Filed on July 30, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx